Cover Image
市場調查報告書

醫療事務的評價 (EU5個國家) :多發性硬化症

Medical Affairs Reputations (EU5): Multiple Sclerosis

出版商 FirstWord 商品編碼 336409
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
醫療事務的評價 (EU5個國家) :多發性硬化症 Medical Affairs Reputations (EU5): Multiple Sclerosis
出版日期: 2015年07月01日 內容資訊: 英文
簡介

本報告以對應多發性硬化症患者的神經科醫生為對象,進行9個多發性硬化症 (MS) 治療藥中至少涉及1個的醫療事務 (MA) 相關意見調查,醫生想得到來自MA團隊幫助的重要問題,醫生對於MA團隊的整體實際成果滿足程度,以及如何改善實際成果,未滿足醫生需求的是MA團隊所提供服務的哪個方面,及醫生喜歡與MA專家交流的方法等相關資料彙整。

對象的治療藥

  • Bayer
    • Betaseron (干擾素-β-1b)
  • Biogen
    • Avonex (干擾素-β-1a)
    • Tecfidera (富馬酸二甲酯)
    • Tysabri (Natalizumab)
  • Merck Serono
    • Rebif (干擾素-β-1a)
  • Novartis
    • Extavia (干擾素-β-1b)
    • Gilenya (Fingolimod)
  • Sanofi
    • Aubagio (Teriflunomide)
  • Teva
    • Copaxone (Glatiramer acetate)

目錄

  • 調查的目標、目的
  • 摘要整理
  • 跟各醫療事務隊的交流現狀
  • 各種特質相關醫療事務隊的實際成果的競爭評估
  • 喜好的交流媒體、頻率,及改善的建議
  • 附錄
目錄
Product Code: 596200403

Compare how well pharma Medical Affairs teams perform and find out which ones physicians rate, in our exclusive report on the Multiple Sclerosis sector. See how well your team stacks up against the competition and where work is still needed.

As well as this timely report weighing up the performance of the European Medical Affairs teams, you can also get an equivalent report for the US. If you buy both reports, we'll save you time and effort by giving you an additional free report that clearly sets out the differences in findings between both regions.

We asked neurologists who see patients with Multiple Sclerosis for their opinions on the Medical Affairs professionals they had dealt with in relation to at least one of the 9 MS drugs considered. Their frank responses reveal key areas of concern for you and what you should focus on to improve neurologists' satisfaction. Areas where the teams are giving a solid performance are also highlighted.

Get Answers to Key Questions

  • What are the critical issues that physicians want help with from European Medical Affairs (MA) teams on?
  • How satisfied are physicians with the overall performance of MA teams? And how can performance be improved?
  • Which aspects of the services MA teams are providing are failing to satisfy physicians' needs?
  • What are the preferred ways in which physicians want to interact with MA experts?
  • Which MA teams do physicians rate the best or worst for the products surveyed?

Products Included in Report

  • Bayer
    • Betaseron (Interferon-beta-1b)
  • Biogen
    • Avonex (Interferon-beta-1a)
    • Tecfidera (Dimethyl Fumarate)
    • Tysabri (Natalizumab)
  • Merck Serono
    • Rebif (Interferon-beta-1a)
  • Novartis
    • Extavia (Interferon-beta-1b)
    • Gilenya (Fingolimod)
  • Sanofi
    • Aubagio (Teriflunomide)
  • Teva
    • Copaxone (Glatiramer acetate)

Key Issues Explored

  • How physicians use the services of Medical Affairs teams
  • The importance of responding promptly to medical inquiries
  • The need-gap analysis of Medical Affairs roles - collectively and by product
  • The importance to physicians of regular, accurate, unbiased scientific and product information
  • Which Medical Affairs teams are performing best and worst for the Multiple Sclerosis sector

Table of Contents

  • Research aims and objectives
  • Executive summary
  • Current status of interactions with different Medical Affairs teams
  • Competitive evaluation of Medical Affairs teams' performance on various attributes
  • Preferred interaction media, frequency, and suggestions for improvement
  • Appendix
Back to Top